ReviewAnnals of translational medicine2016
The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics.
Review in Annals of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Tumor-derived systems as novel biomedical tools-turning the enemy into an ally.Biomaterials research · 2023Review
- Review
- How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review.Translational lung cancer research · 2021Review
- Immunotherapy in malignant pleural mesothelioma: a review of literature data.Translational lung cancer research · 2021Review
- The Statistical Evaluation of Treatment and Outcomes in Head and Neck Squamous Cell Carcinoma Clinical Trials.Frontiers in oncology · 2019Review
- Overall success rate of a safe and efficacious drug: Results using six phase 1 designs, each followed by standard phase 2 and 3 designs.Contemporary clinical trials communications · 2018Article
- Interim Futility Monitoring Assessing Immune Therapies With a Potentially Delayed Treatment Effect.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Article
- Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect.Trends in immunology · 2018Review
- Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L.Journal of hepatocellular carcinoma · 2017Article
- Overview of advances in cancer immunotherapy.Annals of translational medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapy has had a major impact on the established paradigms of drug development and clinical trial research. The innovative mechanism of action of these compounds has resulted in new patterns of response and safety profiles, which pose challenges for the classical trial methodology. In this review we report on the search for the maximum tolerated dose, the recommended phase II dose and the appropriate target population in phase I trials. We provide some statistical considerations on the choice of endpoints for phase II and III trials and the limitations of frequently used trial designs in the presence of a delayed treatment effect, which may be induced by the immune modulating effect of the checkpoint inhibitors. We summarize the currently available data on the safety profile of these new compounds, which can guide protocol safety recommendations. Finally, we report on the current evidence of biomarker development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.